- Home
- KNOP vs AARD Comparison
KNOP vs AARD Comparison
Compare KNOP & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | AARD |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.5M | 297.2M |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | KNOP | AARD |
|---|---|---|
| Price | $10.48 | $15.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $31.11 |
| AVG Volume (30 Days) | 109.6K | ★ 214.6K |
| Earning Date | 12-04-2025 | 02-14-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $352,712,000.00 | N/A |
| Revenue This Year | $14.84 | N/A |
| Revenue Next Year | $1.98 | N/A |
| P/E Ratio | $8.90 | ★ N/A |
| Revenue Growth | ★ 17.65 | N/A |
| 52 Week Low | $5.29 | $4.88 |
| 52 Week High | $11.10 | $19.58 |
Technical Indicators
Market Signals| Indicator | KNOP | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 65.04 |
| Support Level | $10.06 | $14.25 |
| Resistance Level | $11.10 | $16.00 |
| Average True Range (ATR) | 0.27 | 0.96 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 40.38 | 72.38 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.